Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase

AIDS

Volumn 20, Issue 11, 2006, Pages 1515-1520

  Berkhout, Ben ^a   Back, Nicole K T ^a   De Ronde, Anthony ^a   Jurriaans, Suzanne ^a   Bakker, Margreet ^a   Parkin, Neil T ^b   Van Der Hoek, Lia ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MONOGRAM BIOSCIENCES   (United States)

Author keywords

Drug resistance mutations; Evolution; HIV 1; Reverse transcriptase

Indexed keywords

ABACAVIR; AMINO ACID; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; DATA BASE; DRUG SENSITIVITY; GENOTYPE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MUTANT; MUTATION; MUTATIONAL ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN VARIANT; SEQUENCE ANALYSIS;

ANTI-HIV AGENTS; DATABASES, GENETIC; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33746216625     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000237367.56864.75     Document Type: Article

References (18)

1. De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2004; 2:704-720.
2. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: fall. Top HIV Med 2005; 13:125-131.
3. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der NJ. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495-503.
4. Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, de Wolf F, et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS 2004; 18:1571-1577.
5. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-928.
6. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-799.
7. Yerly S, Rakik A, Kinloch de Loes S, Hirschel B, Descamps D, Brun-Vezinet F, et al. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconverters infected with zidovudine-resistant variants. J Virol 1998; 72:3520-3523.
8. de Ronde A, van Dooren M, van der Hoek L, Bouwhuis D, de Rooij E, Van Gemen B, et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001; 75:595-602.
9. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, et al. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000; 14:163-171.
10. Masquelier B, Descamps D, Carriere I, Ferchal F, Collin G, Denayrolles M, et al. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lami vudine in the delta lami vudine roll-over study. Antiviral Ther 1999; 4:69-77.
11. St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-1559.
12. Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 2002; 16:F41-F47.
13. Larder BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992; 36:2664-2669.
14. Richman DD, Shih CK., Lowy I, Rose J, Prodanovich P, Goff S, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A 1991; 88:11241-11245.
15. Berkhout B. HIV-1 evolution under pressure of protease inhibitors, climbing the stairs of viral fitness. J Biomed Sci 1999; 6:298-305.
16. Keulen W, Boucher C, Berkhout B. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antiviral Res 1996; 31:45-57.
17. Berkhout B, de Ronde A. APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 2004; 18:1861-1863.
18. Keulen W, Back NK, van Wijk A, Boucher CA, Berkhout B. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1997; 71:3346-3350.